TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Infants Who Met Composite Safety Endpoint (Grade 3/4 Adverse Event, Adverse Birth Outcome, Death)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in CD3+ lymphocyte subset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: success rate of airway cleaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in isokinetic strength measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery at 3 Months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Positron emission tomography results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum-tolerated dose of azacitidine
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From Clinically Significant PE or Fatal PE
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness of amblyopia treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stiffness of the myometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in hemoglobin A1c level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite of Death and Rehospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Days Alive and Out of Hospital (DAOH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Therapy-Related Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in salivary cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in PPPASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invasive blood pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Saliva Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EGFR TKI sensitivity biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of germline and somatic mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the plasma concentration-time curves (AUC) for metamizole and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Trough Supine Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical resolution of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage With Growth Hormone (GH) Suppression to < 0.4 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PENG Block depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Hearing Performance Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic post-procedural pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slowdown of PAD progression based on ABI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Diaphragmatic Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Symptom-Free Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of biologically confirmed cases of pertussis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intraoperative detection of fluorescence in pelvic lymphatic tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfusion in lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Number of participants newly diagnosed with breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Safety of AERAS 404 injections
Endpoint domain: Adverse events/effects
Primary endpoint: Pain-Free at 2 Hours Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Pain-Free From 2-24 Hours Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of digital models in arch analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of venous thrombo-embolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Safety and tolerability of PD-0360324
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum TPOAb titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: General Health Questionnaire-12 (GHQ-12) continuous total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Depression Intensity Scale Circles (DISCS) continuous total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Specific B cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specific T cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nurse's preference to use the test product
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Modified WOMAC scores for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percent of HPV vaccination initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes from baseline CLVQOL scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mRNA expression levels for outcome prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: miRNA patterns with prognostic significance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percentage of Time That INR Within Therapeutic Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical Lordosis Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric pain rating scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Symptom-limit exercise tolerance tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy and safety of doxorubicin with or without dexrazoxane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of hyperfractionated radiation plus standard intrathecal chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative efficacy and toxicity of E.coli and Erwinia asparaginase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative efficacy and toxicity of cranial radiation delivered in once-daily versus twice-daily fractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Diameter Stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Urine Microalbumin Creatinine Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in sensory thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GI symptoms severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reproducibility of ABC or vDIBH set-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Maternal Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Fetal Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Montgomery Asberg Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cmax at Single Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast at Single Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1/2 at Single Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ceoi at Multiple Doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with improvement in dryness, pain, or fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proportion of patients with improvement in dryness, pain, or fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in transition readiness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients developing treatment failure
Endpoint domain: Adverse events/effects
Primary endpoint: Intubation Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mid-band fit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spectral intercept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spectral slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity and frequency of Diarrheic Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Physiological Changes (heart rate and oxygen saturation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes in oral health related quality of life after orthognathic surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: changes in health related quality of life after orthognathic surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants Who Developed Factor IX Inhibitor
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Allergic Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Thrombotic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in cardiopulmonary exercise performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Dementia Rating Scale (DRS) Memory Subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CIBIC-Plus Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 12 Weeks of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 48 Weeks of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 100 Weeks of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: CD34+ peripheral blood stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: overall rate of biochemical progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to biochemical progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall rate of clinical progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of Lifting Flaps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of balancing behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini-Balance Evaluation Systems Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of gait performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in omega-3 index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: degree of food stasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Identification rate and accuracy of RISAS-procedure for axillary pCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: AUC(0-24) after single dose on Cycle 1 Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequacy of nursing care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Severity of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinical Cure at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With No Revision Surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Presence/absence of documented fungal infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence/absence of clinical fungal infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total duration of high fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total duration of antibiotic treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diabetes Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reoperation/Rehospitalization Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Predicted Annual Rate of Change in 10 Year Risk of Fatal or Nonfatal Heart Attack or Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with hypotensive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pain scale (Numeric Rating Scale 0-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower leg circumference (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee extensor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Side-Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with 4-Fold or Greater HAI Antibody Titer Increases Against H1N1 Virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Reporting Solicited Subjective Systemic Reactions After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Vaccine-Associated Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Filling cystometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Uroflowmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Dexmedetomidine pharmacokinetic curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obstructive limitation in pulmonary function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Antileukemic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical outcomes after treatment of long bone metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of percent of total radioactivity recovered in urine and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total radioactivity concentration equivalents in plasma and blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plazomicin concentrations in plasma and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evaluation of CD8 immune biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients hospitalized in intensive care for SARS-Cov-2 viral lung infection
Endpoint domain: Mortality/survival
Primary endpoint: Parental Assessment of Cutaneous Tolerance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Global Assessment of Cutaneous Tolerance
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: QRS interval duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal tolerable dose (MTD) absorbed dose to the liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to treatment failure (TTF)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in electromyography (EMG) test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of restenosis after angioplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC0-t for SLV337
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for SLV337
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 for SLV337
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in activity counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of atiprimod
Endpoint domain: Adverse events/effects
Primary endpoint: Correlation of PET CT with surgical resection outcomes in NSCLC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Foot tissue oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-emergent SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Time for Image Interpretation (Mean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for Image Interpretation (Mean - Scaled)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for Image Interpretation (Median - Scaled)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of cardiac ion channelopathy mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: quantitative analysis of circulating tumour cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Yale Brown Obsessive Compulsive Scale (YBOCS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnosed sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive Composite changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prostate Specific Antigen Doubling Time (PSADT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Toxicities associated with CyberKnife treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance of APAP and CPAP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Palliative pain response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of HIT associated with UFH and LMWH
Endpoint domain: Adverse events/effects
Primary endpoint: Outcomes of patients with HIT
Endpoint domain: Physiological/clinical
Primary endpoint: Adverse events associated with alternative anticoagulants used to treat HIT
Endpoint domain: Adverse events/effects
Primary endpoint: Low Back Pain related-Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Serious Device Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: VO2 max test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hormonal status association
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in arterial stiffness/intima thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Six minute walking test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of chronic pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Rate of patients cured
Endpoint domain: Mortality/survival
Primary endpoint: Rate of patients pauci-symptomatic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-transport of low urgency EMS case
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Hyperhidrosis disease severity score (HDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digital Rectal Examination (DRE) results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum Levels of Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes